Trial completion date • Combination therapy • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • B2M (Beta-2-microglobulin) • RAD51 (RAD51 Homolog A) • CD4 (CD4 Molecule) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • NTRK (Neurotrophic receptor tyrosine kinase) • SLC7A11 (Solute Carrier Family 7 Member 11) • UBE2M (Ubiquitin Conjugating Enzyme E2 M) • ATF3 (Activating Transcription Factor 3) • NAE1 (NEDD8 Activating Enzyme E1 Subunit 1)
|
BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression
|
carboplatin • paclitaxel • pevonedistat (MLN4924)